Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors
| Autor: | Robin Sommers, Jean Boucher |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Antineoplastic Agents Hormonal medicine.medical_treatment Octreotide Ovary Neuroendocrine tumors Lutetium Patient care 030218 nuclear medicine & medical imaging Targeted therapy 03 medical and health sciences 0302 clinical medicine Stomach Neoplasms Internal medicine Intestinal Neoplasms medicine Humans General Environmental Science Aged Aged 80 and over Lung business.industry Thyroid Middle Aged medicine.disease Pancreatic Neoplasms Neuroendocrine Tumors medicine.anatomical_structure Somatostatin 030220 oncology & carcinogenesis General Earth and Planetary Sciences Female Radiopharmaceuticals business medicine.drug |
| Zdroj: | Clinical journal of oncology nursing. 22(5) |
| ISSN: | 1538-067X |
| Popis: | Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with advanced GEP-NETs. Patients treated with octreotide long-acting release may be candidates for this second-line therapy. This article discusses lutetium Lu 177 dotatate therapy administration and patient care considerations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|